Background In May, 2022, several European countries reported autochthonous cases of
monkeypox, which rapidly spread globally. Early reports suggest atypical presentations. We …

Background People living with HIV have accounted for 38–50% of those affected in the 2022
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …

Background Scarce data are available on what variables affect the risk of transmission of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the development of …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …

Background No effective treatments for coronavirus disease 2019 (COVID-19) exist. We
aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be …

Background Monkeypox DNA has been detected in skin lesions, saliva, oropharynx, urine,
semen, and stool of patients infected during the 2022 clade IIb outbreak; however, the viral …

Background Current strategies for preventing severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. …

Background Outpatient monoclonal antibodies are no longer effective and antiviral treatments
for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many …

Background Since May, 2022, a large global outbreak of human mpox (formerly known as
monkeypox) has predominantly affected men who have sex with men. The strain responsible, …

We read with interest the recent article by Collins et al. 1 regarding under-identification of
hospital clusters of Group B Streptococcus (GBS) disease outbreaks. The first step in …